Comparative study of allogenic and xenogeneic mesenchymal stem cells on cisplatin-induced acute kidney injury in Sprague-Dawley rats

Table 4 Number of proliferating cells/HPF identified by Ki67 in the renal cortex and OSOM of different experimental groups

	Group I	Group II	Group III	Group IV	Group V	Group VI
	negative control	cisplatin ‘CDDP’-treated	cisplatin + rBMSCs-treated	cisplatin + hADSCs-treated (n = 20)	cisplatin + hAFSCs-treated	cisplatin + DMEM culture media-treated
Renal cortex
Day 4	6.0 ± 1.58	8.6 ± 1.14	20.8 ± 2.77^ab	18.8 ± 1.30^ab	18.8 ± 3.34^ab	8.4 ± 1.14^cde
Day 7	9.0 ± 1.58	13.8 ± 2.38	26.4 ± 3.05^ab	17.8 ± 1.92^ac	16.4 ± 5.59^ab	12.2 ± 1.92^c
Day 11	7.4 ± 1.34	16.4 ± 3.05	18.0 ± 3.16^a	33.8 ± 5.54^abc	42.4 ± 6.69^abc	25.0 ± 4.12^ae
Day 30	7.4 ± 1.14	36.0 ± 2.91^a	29.6 ± 2.88^ab	25.8 ± 2.95^ab	26.2 ± 3.03^ab	34.4 ± 3.05^ade
OSOM
Day 4	6.0 ± 1.58	6.8 ± 1.92	22.2 ± 2.28^ab	21.6 ± 2.40^ab	23.4 ± 3.64^ab	14.8 ± 3.96^abcde
Day 7	8.0 ± 1.58	12.4 ± 2.07	29.6 ± 1.67^ab	30.0 ± 3.16^ab	23.4 ± 7.30	21.8 ± 2.86^abc
Day 11	7.0 ± 1.58	13.8 ± 2.86	29.6 ± 5.55^ab	26.8 ± 3.27^ab	26.2 ± 2.38^ab	23.6 ± 3.84^ab
Day 30	6.8 ± 0.83	37.4 ± 5.27^a	30.6 ± 7.92^a	31.6 ± 2.70^a	25.0 ± 4.12^a	37.6 ± 3.64^ae

Values are expressed as mean ± SD. A significant difference (P < 0.05) between different groups was done by Bonferroni post hoc for multiple comparisons
HPF high power field, OSOM outer strip of outer medulla, rBMSCs rat bone marrow stem cells, hADSCs human adipose tissue-derived stem cells, hAFSCs human amniotic fluid-derived stem cells, DMEM Dulbecco’s modified Eagle’s medium
^aSignificant difference vs. negative control group ^bSignificant difference vs. cisplatin-treated group ^cSignificant difference vs. cisplatin + rBMSCs-treated group ^dSignificant difference vs. cisplatin + hADSCs-treated group ^eSignificant difference vs. cisplatin + hAFSCs-treated group

ISSN: 1757-6512